See more : Mednow Inc. (MDNWF) Income Statement Analysis – Financial Results
Complete financial analysis of BioAtla, Inc. (BCAB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioAtla, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- MODEC, Inc. (6269.T) Income Statement Analysis – Financial Results
- Dhanuka Agritech Limited (DHANUKA.NS) Income Statement Analysis – Financial Results
- Cravatex Limited (CRAVATEX.BO) Income Statement Analysis – Financial Results
- Trafalgar Property Group plc (TRAF.L) Income Statement Analysis – Financial Results
- Star Mica Holdings Co., Ltd. (2975.T) Income Statement Analysis – Financial Results
BioAtla, Inc. (BCAB)
About BioAtla, Inc.
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 250.00K | 429.00K | 5.20M | 10.63M |
| Cost of Revenue | 103.73M | 1.20M | 1.33M | 19.93K | 25.92K | 26.31M |
| Gross Profit | -103.73M | -1.20M | -1.08M | 409.07K | 5.17M | -15.68M |
| Gross Profit Ratio | 0.00% | 0.00% | -432.00% | 95.35% | 99.50% | -147.53% |
| Research & Development | 103.73M | 79.35M | 58.27M | 19.93M | 25.92M | 26.31M |
| General & Administrative | 25.96M | 28.79M | 38.42M | 10.60M | 7.55M | 12.56M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 25.96M | 28.79M | 38.42M | 10.60M | 7.55M | 12.56M |
| Other Expenses | 0.00 | 10.00K | 1.00K | -1.00K | -22.00K | -5.00K |
| Operating Expenses | 129.69M | 108.14M | 96.69M | 30.53M | 33.47M | 38.86M |
| Cost & Expenses | 129.69M | 108.14M | 96.69M | 30.53M | 33.47M | 38.86M |
| Interest Income | 6.31M | 1.65M | 350.00K | 100.00K | 128.00K | 209.00K |
| Interest Expense | 0.00 | 3.00K | 1.39M | 1.63M | 949.00K | |
| Depreciation & Amortization | 1.22M | 1.20M | 1.33M | 1.01M | 860.00K | 794.00K |
| EBITDA | -122.24M | -106.48M | -94.07M | -33.46M | -27.37M | -27.24M |
| EBITDA Ratio | 0.00% | 0.00% | -37,903.60% | -6,758.04% | -525.04% | -256.29% |
| Operating Income | -129.69M | -108.14M | -96.44M | -30.10M | -28.27M | -28.23M |
| Operating Income Ratio | 0.00% | 0.00% | -38,576.00% | -7,016.08% | -543.62% | -265.68% |
| Total Other Income/Expenses | 6.23M | 1.66M | 1.04M | -5.75M | -1.59M | -745.00K |
| Income Before Tax | -123.46M | -106.48M | -95.40M | -35.85M | -29.86M | -28.98M |
| Income Before Tax Ratio | 0.00% | 0.00% | -38,160.80% | -8,357.34% | -574.13% | -272.69% |
| Income Tax Expense | 0.00 | -1.20M | 4.00K | 1.39M | 1.55M | 204.00K |
| Net Income | -123.46M | -105.28M | -95.41M | -37.24M | -31.40M | -28.98M |
| Net Income Ratio | 0.00% | 0.00% | -38,162.40% | -8,680.89% | -603.88% | -272.69% |
| EPS | -2.58 | -2.70 | -2.76 | -1.11 | -0.93 | -1.34 |
| EPS Diluted | -2.58 | -2.70 | -2.76 | -1.11 | -0.93 | -1.34 |
| Weighted Avg Shares Out | 47.78M | 38.93M | 34.56M | 33.66M | 33.66M | 21.59M |
| Weighted Avg Shares Out (Dil) | 47.78M | 38.93M | 34.56M | 33.66M | 33.66M | 21.59M |
BioAtla, Inc. (BCAB) Q1 2023 Earnings Call Transcript
BioAtla, Inc. (NASDAQ:BCAB ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Bruce Mackle - IR, LifeSci Advisors, LLC Jay Short - Chairman and CEO Richard Waldron - CFO Philippe Martin - Chief CDO Conference...
BioAtla to Announce First Quarter 2023 Financial Results and Provide Business Highlights on May 11, 2023
SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to...
BioAtla, Inc. (BCAB) Q4 2022 Earnings Call Transcript
BioAtla, Inc. (NASDAQ:BCAB ) Q4 2022 Earnings Call Transcript March 23, 2023 4:30 PM ET Company Participants Bruce Mackle - Investor Relations, LifeSci Advisors, LLC Jay Short - Chairman, Chief Executive Officer and Cofounder Richard Waldron - Chief Financial Officer...
7 Cheap But Risky Biotech Stocks
Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF drop nearly 50%.
Can BioAtla, Inc. (BCAB) Climb 260% to Reach the Level Wall Street Analysts Expect?
The mean of analysts' price targets for BioAtla, Inc. (BCAB) points to a 259.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside...
BioAtla, Inc. (BCAB) Q3 2022 Earnings Call Transcript
BioAtla, Inc. (NASDAQ:BCAB ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Bruce Mackle - Investor Relations Jay Short - Chairman, Chief Executive Officer and Co-Founder Scott Smith - President Philippe Martin - Chief, Clinical...
BioAtla, Inc. (BCAB) Reports Q3 Loss, Lags Revenue Estimates
BioAtla, Inc. (BCAB) delivered earnings and revenue surprises of 10.39% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
BioAtla to Announce Third Quarter 2022 Financial Results and Provide Business Highlights on November 3, 2022
SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to...
BioAtla: Back From The Dead
Shares of conditionally active biologics concern BioAtla, Inc. are beginning to rebound from a 97% plunge as encouraging data from two candidates has sparked the turnaround. BioAtla leverages its expertise of the tumor microenvironment to develop highly selective and reversible...
BioAtla: Promising Signal In NSCLC, But Concerns Remain
BioAlta shares have lost nearly three-quarters of their value over the past 3 years. Management has not done a good job of keeping lines of communication open and has a history of postponing clinical data timelines.
Source: https://incomestatements.info
Category: Stock Reports